These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7000408)

  • 1. MLC-blocking factors in uremic sera.
    Fehrman I; Ringdén O; Bergström J
    Clin Nephrol; 1980 Oct; 14(4):183-9. PubMed ID: 7000408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L; Kálmán K; Hauck M; Kakuk G
    Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed lymphocyte culture (MLC) inhibition in humans due to anti-Ia like (DRW).
    Soulillou JP; Naud MF; Peyrat MA; Guenel J
    Pathol Biol (Paris); 1978 Dec; 26(9-10):547-51. PubMed ID: 154642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H; Alvestrand A; Fürst P; Bergström J
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of varying dialysis regimens on lymphocyte stimulation.
    Hurst KS; Saldanha LF; Steinberg SM; Galen MA; Lowrie EG; Gagneux SA; Lazarus JM; Strom TB; Carpenter CB; Merrill JP
    Trans Am Soc Artif Intern Organs; 1975; 21():329-34. PubMed ID: 1146004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation.
    Barocci S; Valente U; Nocera A
    Clin Transplant; 2007; 21(1):47-56. PubMed ID: 17302591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The humoral responses of haemodialysis patients to antigen challenge.
    Castro JE; Mee AD
    Transplantation; 1976 Jul; 22(1):18-23. PubMed ID: 132722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
    Severini G; Diana L; Di Giovannandrea R; Sagliaschi G
    ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific inhibition of HLA class I and II antibodies by soluble antigens--a method for the identification of antibody specificity in sera from alloimmunized individuals.
    Sumitran-Karuppan S; Möller E
    Transplantation; 1994 Sep; 58(6):713-9. PubMed ID: 7940692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous release of leukocyte migration inhibition factor (LMIF) by lymphocytes in chronic lymphatic leukemia patients.
    Crivii SM; Crişan M; Crişan M
    Arch Geschwulstforsch; 1984; 54(1):85-9. PubMed ID: 6367694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha.
    Allen DA; Breen C; Yaqoob MM; Macdougall IC
    J Investig Med; 1999 May; 47(5):204-11. PubMed ID: 10361379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cytotoxic properties of plasma fractions from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Artif Organs; 1981; 4 Suppl():68-70. PubMed ID: 7295099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An effect of chromatographic fraction ultrafiltrate of plasma on aggregation of blood platelets in patients with chronic uremia].
    Popławski A; Myśliwiec M
    Pol Merkur Lekarski; 1996 Oct; 1(4):246-8. PubMed ID: 9156935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uremia as a state of immune deficiency.
    Birkeland SA
    Scand J Immunol; 1976; 5(1-2):107-15. PubMed ID: 131369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components.
    Kamata K; Okubo M; Sada M
    Clin Exp Immunol; 1983 Oct; 54(1):277-81. PubMed ID: 6616971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Variations in prolactinemia in 26 uremic subjects treated by periodic hemodialysis].
    Deambrogio P; Vanni M; Aleo AG
    Minerva Med; 1985 Apr; 76(17-18):847-9. PubMed ID: 4000528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the mixed leukocyte reaction by alloantisera in man. II. Incidence and characteristics of MLC-inhibiting antisera from multiparous women.
    Jonker M; van Leeuwen A; van Rood JJ
    Tissue Antigens; 1977 May; 9(5):246-58. PubMed ID: 142317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.